A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

BIOLOGICAL: Patritumab deruxtecan
DRUG: Paclitaxel
DRUG: Nab-paclitaxel
DRUG: Capecitabine
DRUG: Liposomal doxorubicin
BIOLOGICAL: Trastuzumab deruxtecan

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]